Literature DB >> 23903841

A novel influenza virus hemagglutinin-respiratory syncytial virus (RSV) fusion protein subunit vaccine against influenza and RSV.

Tiffany M Turner1, Les P Jones, S Mark Tompkins, Ralph A Tripp.   

Abstract

Influenza A virus and respiratory syncytial virus (RSV) cause substantial morbidity and mortality afflicting the ends of the age spectrum during the autumn through winter months in the United States. The benefit of vaccination against RSV and influenza using a subunit vaccine to enhance immunity and neutralizing antibody was investigated. Influenza virus hemagglutinin (HA) and RSV fusion (F) protein were tested as vaccine components alone and in combination to explore the adjuvant properties of RSV F protein on HA immunity. Mice vaccinated with HA and F exhibited robust immunity that, when challenged, had reduced viral burden for both influenza and RSV. These studies show an enhancing and cross-protective benefit of F protein for anti-HA immunity.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23903841      PMCID： PMC3807402          DOI： 10.1128/JVI.01724-13

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  94 in total

1.  Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group.

Authors:  M Sorrentino; T Powers
Journal:  Pediatr Infect Dis J       Date:  2000-11       Impact factor: 2.129

2.  Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.

Authors:  Lia M Haynes; Les P Jones; Albert Barskey; Larry J Anderson; Ralph A Tripp
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

3.  Severe respiratory disease concurrent with the circulation of H1N1 influenza.

Authors:  Gerardo Chowell; Stefano M Bertozzi; M Arantxa Colchero; Hugo Lopez-Gatell; Celia Alpuche-Aranda; Mauricio Hernandez; Mark A Miller
Journal:  N Engl J Med       Date:  2009-06-29       Impact factor: 91.245

4.  Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion.

Authors:  Bert Schepens; Lorena Itatí Ibañez; Sarah De Baets; Anna Hultberg; Pieter Bogaert; Pieter De Bleser; Frederik Vervalle; Theo Verrips; José Melero; Wesly Vandevelde; Peter Vanlandschoot; Xavier Saelens
Journal:  J Infect Dis       Date:  2011-10-12       Impact factor: 5.226

5.  Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB.

Authors:  S Tamura; H Funato; T Nagamine; C Aizawa; T Kurata
Journal:  Vaccine       Date:  1989-12       Impact factor: 3.641

6.  Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.

Authors:  M Connors; N A Giese; A B Kulkarni; C Y Firestone; H C Morse; B R Murphy
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

7.  Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.

Authors:  Wenliang Zhang; Youngjoo Choi; Lia M Haynes; Jennifer L Harcourt; Larry J Anderson; Les P Jones; Ralph A Tripp
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

8.  Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis.

Authors:  P A Piedra; S Grace; A Jewell; S Spinelli; D Bunting; D A Hogerman; F Malinoski; P W Hiatt
Journal:  Pediatr Infect Dis J       Date:  1996-01       Impact factor: 2.129

9.  Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.

Authors:  B R Murphy; E E Walsh
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

10.  Baculovirus-based Vaccine Displaying Respiratory Syncytial Virus Glycoprotein Induces Protective Immunity against RSV Infection without Vaccine-Enhanced Disease.

Authors:  Sol Kim; Jun Chang
Journal:  Immune Netw       Date:  2012-02-29       Impact factor: 6.303
View more
  3 in total

Review 1.  Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.

Authors:  Shujing Wang; Huiqin Liu; Xinyi Zhang; Feng Qian
Journal:  Protein Cell       Date:  2015-05-06       Impact factor: 14.870

2.  Hyperosmolarity impedes the cross-priming competence of dendritic cells in a TRIF-dependent manner.

Authors:  Zoran V Popovic; Maria Embgenbroich; Federica Chessa; Viola Nordström; Mahnaz Bonrouhi; Thomas Hielscher; Norbert Gretz; Shijun Wang; Daniel Mathow; Thomas Quast; Jan-Gero Schloetel; Waldemar Kolanus; Sven Burgdorf; Hermann-Josef Gröne
Journal:  Sci Rep       Date:  2017-03-22       Impact factor: 4.379

3.  Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease.

Authors:  Silvestro Ennio D'Anna; Mauro Maniscalco; Francesco Cappello; Mauro Carone; Andrea Motta; Bruno Balbi; Fabio L M Ricciardolo; Gaetano Caramori; Antonino Di Stefano
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.